Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIEX (Plant-Identical Extracts) is a line of full-spectrum cannabis extracts developed by the German company Becanex GmbH for use as active pharmaceutical ingredients (APIs) in medical therapy. These extracts are produced using a proprietary one-step extraction technology designed to preserve the natural ratio of phytocannabinoids (primarily THC and CBD) and terpenes found in the source cannabis flower. This plant-identical profile is intended to facilitate the "entourage effect," where terpenes modulate the activity of cannabinoids to enhance therapeutic efficacy and reduce side effects. PIEX is available in various formulations, such as PIEX 2 (containing 70% THC), and is intended for individualized cannabis-based medical therapy. While primarily administered sublingually via a dosed pipette, feasibility studies have validated its use for inhalation via medical vaporizers such as the MIGHTY+ MEDIC and VOLCANO MEDIC. It is positioned as a natural alternative to synthetic cannabinoids like dronabinol, offering precise dosing and easier handling due to its honey-like viscosity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PIEX.